Drug intelligence / Profile preview

STI-2020dna

Development stage: Preclinical
Lead developer: Sorrento Therapeutics
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
Administration: Injection

Overview

STI-2020dna is a gene therapy developed by Sorrento Therapeutics, following its acquisition of SmartPharm Therapeutics. This drug is a DNA plasmid designed to encode and deliver Sorrento's STI-1499 antibody. Utilizing SmartPharm's non-viral gene delivery platform, STI-2020dna aims to enable the patient's body to produce its own neutralizing antibodies internally for extended periods, primarily targeting COVID-19. The technology is also intended for future applications in cancer and rare diseases, offering a potentially cost-effective and long-lasting therapeutic or prophylactic approach.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on STI-2020dna.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STI-2020dna.

Explore the full profile